Sort by
Refine Your Search
-
to starting the post. Expert knowledge of gravitation. This should include one or more of the following: gravitational-wave modelling or data analysis, black hole perturbations, mathematical or numerical
-
to starting the post. Expert knowledge of gravitation. This should include one or more of the following: gravitational-wave modelling or data analysis, black hole perturbations, mathematical or numerical
-
working will be considered. Contract type: Permanent Salary: Full time starting salary is normally in the range of £37,337 to £44,906 per annum, with potential progression up to £51,298 per annum; If PhD is
-
UKESM1 or similar models, advanced data analysis and machine learning, would be advantageous. Grade E: You will be near completion of a relevant PhD or have equivalent research experience, and be able
-
teamworking skills. Relevant technical skills include heterogeneous catalysis/chemical reaction engineering, materials characterisation (e.g. thermogravimetric analysis, dielectric property measurements
-
experiments and test candidate therapeutics on leukaemic stem cells isolated from primary patient samples. You will be responsible for carrying out laboratory research, data analysis and presentation of results
-
experiments and test candidate therapeutics on leukaemic stem cells isolated from primary patient samples. You will be responsible for carrying out laboratory research, data analysis and presentation of results
-
teamworking skills. Relevant technical skills include heterogeneous catalysis/chemical reaction engineering, materials characterisation (e.g. thermogravimetric analysis, dielectric property measurements
-
to ensure all project deliverables are met. Undertake these responsibilities in the project: i. DHI Mike Modelling: Utilize DHI Mike software to develop and validate numerical models for wave propagation and
-
have recently developed a new method of statistical analysis for the problem of finding the key genes for disease, with exciting pilot results and promising drug targets for rheumatoid arthritis and